Delcath Systems Inc (DCTH) 13F Filing Data & Analysis (Q2 2026)

DCTH ranks #4134 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

DCTH is a top-conviction position for Rosalind Advisors, Inc. — at 15.4% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

Propel Bio Management, LLC has added to its DCTH position for two straight quarters, increasing it by $6.5M to reach $11.0M today.

Ken Griffin has trimmed its DCTH position for two straight quarters, cutting it by $4.4M while still holding $727.0K.

DCTH is up 1.1% today, and institutions have been net buyers of $25.4M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

DCTH posted net income of $532.0K over the trailing twelve months, and currently trades at a P/E of 1244.1.

• Profitable — net income of $532.0K over the trailing twelve months
• Revenue grew 35.8% year over year
• Net income declined year over year, from $2.2M to $532.0K
• Generated $22.5M in positive operating cash flow
• Current ratio of 10.92x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.11x equity — within a conventional range